Bristol-Myers Squibb ($BMS) has become the latest large drug developer to hitch its R&D operation to Medidata’s ($MDSO) cloud-based suite of tools. The arrangement will see Bristol-Myers rely on Medidata’s technologies to run and analyze clinical trials of its pipeline experimental treatments for cancer and other indications.
Having signed up to use Medidata Clinical Cloud, Bristol-Myers has now entered a period in which it will progressively implement different parts of the suite. Medidata has tapped Accenture ($ACN) to help with certain elements of the project. By the end of the process, Bristol-Myers will have adopted multiple components of Medidata’s product suite, including the Rave electronic data capture system on which the eClinical player has built its business.
In keeping with Medidata’s recent deals, Bristol-Myers will also make use of other products in the burgeoning suite. Specifically, Bristol-Myers will work with Medidata to implement risk-based clinical trial monitoring, a process that will be underpinned by Medidata TSDV and Medidata CSA. The two pieces of software, respectively, help clinical trial sponsors to identify abnormal data and analyze site quality, capabilities that make it possible to focus resources on areas where they are needed most.
Boehringer Ingelheim, another of the string of companies to ink deals with Medidata in the past six months, has also adopted the risk-based management products. In between the Boehringer and Bristol-Myers deals, Medidata inked an expansion of its relationship with Celgene ($CELG), which started out as a Rave customer eight years ago before ratcheting up the number of tools it sources from the eClinical specialist.
Collectively, the three deals represent a snapshot of the ways in which Medidata is trying to grow its business. The Celgene deal is an example of how Medidata is turning its long-standing Rave clients into buyers of a broader suite of products. And the signing up of Boehringer, which used to be better known for its ties to Medidata’s rival Oracle ($ORCL), is evidence of its ability to pick up competitive wins.
Bristol-Myers has also worked closely with Oracle in the past, even giving a presentation on the value of using the latest version of the software giant’s data capture tool at a conference in 2010.
- read the release